A number of firms have modified their ratings and price targets on shares of Solid Biosciences (NASDAQ: SLDB) recently: 5/3/2022 – Solid Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Solid Biosciences LLC is a life science company. It focuses on developing therapies […]
Equities analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.17). Solid Biosciences […]
Equities research analysts expect that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will post earnings per share of ($0.18) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with estimates ranging from ($0.20) to ($0.17). Solid Biosciences posted earnings of ($0.19) per share during the same quarter […]
Solid Biosciences (NASDAQ:SLDB – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage presently has a $1.25 target price on the stock. Zacks Investment Research‘s target price suggests a potential downside of 11.97% from the company’s current […]